| Literature DB >> 28924600 |
Ann T Ma1, Amélie Therrien1,2, Jeanne-Marie Giard1,2, Daniel von Renteln1,2, Mickael Bouin1,2.
Abstract
BACKGROUND AND AIMS: Colorectal cancer (CRC) is associated with a significantly reduced survival rate in transplant recipients. The prevalence and risk factors of CRC and of colorectal polyps after orthotopic liver transplant (OLT) remain unclear. The study aim was to determine the prevalence of colorectal polyps in OLT recipients. A secondary objective was to explore possible risk factors of polyps. PATIENTS AND MATERIALS: This was a retrospective single center study of all OLT recipients transplanted between 2007 and 2009. All patients who underwent a colonoscopy 5 ± 5 years after OLT were included. The outcome was colorectal polyps, as identified on colonoscopy. A logistic regression model was performed to identify potential predictors of polyps.Entities:
Year: 2017 PMID: 28924600 PMCID: PMC5597935 DOI: 10.1055/s-0043-114660
Source DB: PubMed Journal: Endosc Int Open ISSN: 2196-9736
Fig. 1Flow diagram for all liver transplant recipients. OLT, orthotopic liver transplant; Post, group with only post-transplant colonoscopy; PrePost, group with both pre- and post-transplant colonoscopies.
Characteristics of the 80 liver transplant recipients included in this study.
| Male, n (%) | 51 (64) |
| White ethnicity, n (%) | 74 (93) |
| Age, median [IQR], years | |
At transplant | 57 [10] |
At post-transplant colonoscopy | 60 [11] |
| Median [IQR] years between: | |
Pre-OLT colonoscopy and OLT | 0.5 [0.8] |
OLT and post-OLT colonoscopy | 5.5 [1.8] |
| Active/past smoking, n (%) | 39 (49) |
|
Liver disease before transplant, n (%)
| |
Hepatitis B | 9 (11) |
Hepatitis C | 15 (19) |
Alcoholic liver disease | 23 (29) |
NAFLD | 8 (10) |
PSC | 11 (14) |
Concomitant PSC and IBD | 9 (11) |
PBC | 13 (16) |
AIH | 8 (10) |
Cryptogenic or other | 7 (9) |
| Indication for post-transplant colonoscopy, n (%) | |
Screening | 44 (55) |
Surveillance | 11 (14) |
Diagnostic | 25 (31) |
| CNI-containing regimen, n (%) | 59 (74) |
AIH, autoimmune hepatitis; CNI, calcineurin inhibitor; IBD, inflammatory bowel disease; IQR, interquartile range; NAFLD, nonalcoholic fatty liver disease; OLT, orthotopic liver transplant; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis.
For each case of transplant, there could be more than one liver disease.
Prevalence and histology of polyps and cancerous lesions before and after liver transplant.
|
|
| |
| Patients with polyps, n (%) | 18 (37) | 26 (33) |
|
Patients aged ≥ 50 years
| 17/36 (47) | 26/70 (37) |
| Patients with ≥ 3 polyps, n (%) | 5 (28) | 2 (7) |
| Polyps proximal to splenic flexure, n (%) | 9 (50) | 12 (46) |
| Polyps found on screening colonoscopy, n (%) | 6 (33) | 19 (73) |
| Size ≥ 10 mm, n (%) | 1 (6) | 4 (15) |
| Histology, n (%) | ||
Hyperplastic polyp | 8 (44) | 3 (12) |
Adenoma | 4 (22) | 16 (62) |
| Tubular | 2 | 13 |
| Tubulovillous (HGD) | 0 | 2 (1) |
| Villous (HGD) | 2 (1) | 0 |
| Sessile serrated | 0 | 1 |
Inflammatory polyp | 0 | 1 (4) |
Colorectal cancer | 0 | 1 (4) |
Unavailable | 6 (33) | 5 (19) |
| Advanced adenoma or cancer, n (%) | 2 (11) | 4 (15) |
HGD, high grade dysplasia.
49/80 patients had a pre-transplant colonoscopy.
At time of colonoscopy.
Characteristics of patients with and without post-transplant polyps.
|
|
|
| ||
|
|
| |||
| Male, % | 63.7 | 80.8 | 55.6 | 0.05 |
| ≥ 60 years old, % | 53.8 | 65.4 | 48.1 | 0.16 |
| Current/past smoking, % | 48.8 | 61.5 | 42.6 | 0.15 |
| History of alcoholic liver disease, % | 28.7 | 57.7 | 14.8 | < 0.001 |
| History of NAFLD, % | 80.0 | 11.5 | 13.0 | 1.00 |
| History of IBD/PSC, % | 13.8 | 3.8 | 18.5 | 0.09 |
| CNI-containing regimen, % | 73.8 | 73.1 | 74.1 | 1.00 |
| Presence of pre-transplant polyps, % | 22.5 | 19.2 | 24.1 | 0.78 |
| No pre-transplant colonoscopy, % | 38.8 | 38.5 | 38.9 | 1.00 |
| Colonoscopy post-transplant, % | ||||
Done ≥ 5 years post-transplant | 50.0 | 46.2 | 51.9 | 0.81 |
Done for screening purposes | 55.0 | 73.1 | 46.3 | 0.03 |
CNI, calcineurin inhibitor; IBD, inflammatory bowel disease; NAFLD, nonalcoholic fatty liver disease; PSC, primary sclerosing cholangitis.